Literature DB >> 20707632

Melatonin: pharmacological aspects and clinical trends.

Emiliano Ricardo Vasconcelos Rios1, Edith Teles Venâncio, Nayrton Flávio Moura Rocha, David John Woods, Silvania Vasconcelos, Danielle Macedo, Francisca Cléa Florenço de Sousa, Marta Maria de França Fonteles.   

Abstract

Melatonin, N-acetyl-5-methoxytryptamine, the major hormone produced by the pineal gland under the influence of the dark/light cycle, has been shown to have a large number of therapeutic possibilities. It has been utilized in several countries for circadian rhythm disorders, sleep disturbances, jet lag, and sleep-wake cycle disturbances in blind people, and shift workers. In our mechanism of act, the G(i) protein-coupled metabotropic melatonin receptors MT1 and MT2 are the primary mediators of the physiological actions of melatonin. This hormone plays an important role in the regulation of physiological and neuroendocrine functions, such as synchronization of seasonal reproductive rhythms and entrainment of circadian cycles. In addition to its chronobiological role, several pharmacological effects of melatonin have been reported in mammals including sedative, antioxidant, anxiolytic, antidepressant, anticonvulsant, and analgesic activities. There is some evidence from clinical trials that melatonin can be helpful in that event. Current trends of pharmacological functions of melatonin pointed out its use in the treatment of neurodegenerative and neoplastic diseases. These effects and uses of melatonin are mentioned but further confirmatory studies are needed in most of them.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20707632     DOI: 10.3109/00207454.2010.492921

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  8 in total

Review 1.  Pediatric Sports-Related Concussion: An Approach to Care.

Authors:  Olivia E Podolak; Kristy B Arbogast; Christina L Master; David Sleet; Matthew F Grady
Journal:  Am J Lifestyle Med       Date:  2021-01-21

Review 2.  A new balancing act: The many roles of melatonin and serotonin in plant growth and development.

Authors:  Lauren A E Erland; Susan J Murch; Russel J Reiter; Praveen K Saxena
Journal:  Plant Signal Behav       Date:  2015

3.  Therapeutic applications of melatonin.

Authors:  Ifigenia Kostoglou-Athanassiou
Journal:  Ther Adv Endocrinol Metab       Date:  2013-02       Impact factor: 3.565

4.  Neuronal apoptosis can be prevented by the combined therapy with melatonin and hypothermia in a neonatal rat model of hypoxic-ischemic encephalopathy.

Authors:  Alina Mihaela Toader; Oana Hoteiuc; Cristina Bidian; Dan-Daniel Oltean; Flaviu Tabaran; Ovidiu Grad; Simona Clichici; Daniela Rodica Mitrea
Journal:  Med Pharm Rep       Date:  2021-04-29

5.  Endothelial progenitor cells in acute ischemic kidney injury: strategies for increasing the cells' renoprotective competence.

Authors:  D Patschan; S Patschan; G A Müller
Journal:  Int J Nephrol       Date:  2011-04-27

Review 6.  Melatonin and Ischemic Stroke: Mechanistic Roles and Action.

Authors:  Syed Suhail Andrabi; Suhel Parvez; Heena Tabassum
Journal:  Adv Pharmacol Sci       Date:  2015-09-07

Review 7.  The Uniqueness of Tryptophan in Biology: Properties, Metabolism, Interactions and Localization in Proteins.

Authors:  Sailen Barik
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

8.  A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial.

Authors:  Karen M Barlow; Brian L Brooks; Frank P MacMaster; Adam Kirton; Trevor Seeger; Michael Esser; Susan Crawford; Alberto Nettel-Aguirre; Roger Zemek; Mikrogianakis Angelo; Valerie Kirk; Carolyn A Emery; David Johnson; Michael D Hill; Jeff Buchhalter; Brenda Turley; Lawrence Richer; Robert Platt; Jamie Hutchison; Deborah Dewey
Journal:  Trials       Date:  2014-07-07       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.